Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug discovery that is both first-in-class and best-in-class.

Clostridioides difficile infection (CDI) recurs in one of five patients. Monoclonal antibodies targeting the virulence factor TcdB reduce disease recurrence, suggesting that an inadequate anti-TcdB response to CDI leads to recurrence. In patients with CDI, we discovered that IL-33 measured at diagnosis predicts future recurrence, leading us to test the role of IL-33 signaling in the induction of humoral immunity during CDI. Using a mouse recurrence model, IL-33 was demonstrated to be integral for anti-TcdB antibody production. IL-33 acted via ST2+ ILC2 cells, facilitating germinal center T follicular helper (GC-Tfh) cell generation of antibodies. IL-33 protection from reinfection was antibody-dependent, as μMT KO mice and mice treated with anti-CD20 mAb were not protected. These findings demonstrate the critical role of IL-33 in generating humoral immunity to prevent recurrent CDI. ### Competing Interest Statement W.P. is a consultant for TechLab, Inc., which manufactures diagnostic tests for CDI. The authors declare no other competing interests.

A stay in a hospital might resolve one health challenge. Still, it may introduce another: an intractable infection with Clostridioides difficile (C difficile), wrote an Editors Summary published in the journal Science in October 2024. This bacteria can thrive and produce toxins if antibiotics hinder the normal gut bacteria.

Clostridioides difficile infection (CDI) is a common cause of antibiotic-associated colitis. C. difficile proliferates and produces toxins that damage the colonic epithelium, leading to symptoms ranging from mild diarrhea to severe pseudomembranous colitis. The host's innate response t …

Working with animals, Penn researchers modified the mRNA vaccine to target C. difficile, an infection that kills 30,000 in the U.S. each year.

The group of large clostridial toxins (LCTs) includes toxins A (TcdA) and B (TcdB) from Clostridioides difficile, hemorrhagic and lethal toxins from Paeniclostridium sordellii, alpha toxin from Clostridium novyi (TcnA), and cytotoxin from Clostridium perfringens. These toxins are associated with sev …

Global difficile-associated diarrhea treatment market size is expected at $5.16 Bn by 2028 at a growth rate of 12.1%.

Using COVID-19 vaccine technology, researchers created an mRNA vaccine targeting C difficile, showing strong immune responses in animal studies.

REC-3964 is designed to treat C. diff by selectively inhibiting the glucosyltransferase activity of toxin B produced by the bacterium in the gastrointestinal tract.

The clinical stage company, Recursion, dosed its first participant using a novel therapy that is not an antimicrobial.

In a significant advancement for infectious disease treatment, Penn Medicine and the Children's Hospital of Philadelphia (CHOP)....

NCT04026009.

NCT04026009.

We discuss recent advances in the antimicrobial applications of niclosamide and its derivatives to provide new perspectives in treating infectious diseases.

Global Clostridium Difficile Infections Treatment MarketThe global Clostridium Difficile Infections (CDI) treatment market is poised for significant growth over the next decade. Valued at an impressive USD 809 million in 2023, the market is projected to expand at a robust Compound Annual Growth R...

Acurx reports positive Phase 2 results for CDI treatment ibezapolstat

Clostridioides difficile, a spore-forming and anaerobic gram-positive bacterium, causes a wide-spectrum diarrheal disease that can ultimately lead to life-threatening conditions such as toxic megacolon or colonic perforation.

A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides difficile infection, more commonly known as C. difficile or C. diff.

The microbiome therapeutics market is expected to grow from US 375 92 million in 2022 to US 813 38 million by 2030 it is anticipated to record a CAGR of 10 1 from 2022 to 2030 Microbiome Therapeutics Market Size ...

Scientists in Pennsylvania have developed an experimental mRNA-based vaccine for C. diff bacteria, which often cause recurring, miserable bouts of diarrhea.

Promising advancements are on the horizon that could tackle one of the world’s most challenging […]

Bacteria Striking Back Bacterial infections are much less deadly than they used to be before the introduction of antibiotics. “Before we had antibiotics, infections like scarlet fever could even lead to heart problems. Surgery often led to deadly infections in the blood like bacteremia or septicemia. A World Without Antibiotics Because antibiotics silently save so […]

Earlier attempts at producing vaccines against C. difficile have been unsuccessful, although several are currently in development. A vaccine for C. difficile developed by Pfizer failed in a late-stage trial in 2022.

Researchers are developing what they hope will be the first successful vaccine against the highly contagious and difficult-to-treat Clostridioides difficile bacteria, using the technology behind the revolutionary mRNA vaccines that tackled the coronavirus that caused COVID-19.

Discover the groundbreaking mRNA vaccine developed by University of Pennsylvania and Children's Hospital of Philadelphia to prevent and treat C. difficile

CP101 was superior to placebo in reducing recurrent CDI with a safety profile similar to placebo. https://clinicaltrials.gov/study/NCT03110133.

A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides difficile infection, more commonly known as C. difficile or C. diff. In animal models, this first mRNA-LNP C. difficile vaccine was found to protect against C. difficile first-time infections and relapsing infections by inducing a robust immune response, promote clearance of existing C. diff bacteria from the gut, and even overcome deficits in host immunity to protect animals after infection, according to researchers. The results will pave the way for clinical trials of the vaccine.